Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study by Pérez-Oliva et al. explored how Mahogunin Ring Finger-1 (MGRN1) affects melanocortin-1 receptor (MC1R) signaling, suggesting that MGRN1 competitively inhibits Gαs binding to MC1R, influencing pigment production.

This study found that the Gsdma3 gene is necessary for normal hair follicle differentiation in mice, with its mutation leading to progressive hair loss and defects in hair structure.

This randomized clinical trial compared bimatoprost 0.03% solution and mometasone furoate 0.1% cream for treating alopecia areata in 60 patients, finding that mometasone furoate led to better hair regrowth, while both treatments showed significant effectiveness.

In this study, oral and topical tranexamic acid significantly improved melasma symptoms in 28 female patients, with all showing over 25% improvement and 50% achieving good improvement, while 92.86% experienced no side effects, suggesting it is an effective and safe treatment.

This study found that combination therapy with 5% minoxidil and 0.5% anthralin led to hair regrowth in some patients with severe treatment-resistant alopecia areata, but also caused mild to moderate irritant dermatitis in all participants.

This study found that in male patients with androgenetic alopecia, combining botulinum toxin type A with 5% Minoxidil significantly improved hair growth, patient satisfaction, and quality of life over six months, compared to using Minoxidil alone, without causing adverse effects.

This study found that systemic administration of NDP-MSH, a melanocortin receptor agonist, provided neuroprotective effects on dopaminergic nigrostriatal neurons in a mouse model of Parkinson's disease, reducing neuroinflammation and suggesting a role for regulatory T cells in these neuroprotective effects.

In this case report, a 16-year-old girl with adolescent androgenetic alopecia showed visible improvement in hair density after 2 years of treatment with 3% topical minoxidil, despite a family history of the condition and normal hormone levels.

This study suggests that αMSH may play a regulatory role in human dermal papilla cells, potentially influencing immune and inflammatory responses in hair follicles, which could contribute to inflammatory alopecia.

This study found that the mutant hairless rhino bald protein in mice interacts with the vitamin D receptor but cannot repress its transactivation and shows abnormal cellular localization.

This article describes the potential applications of myoblast implantation for muscle regeneration and its promising social and economic value but reports no new clinical results.

In this study, researchers found that mogamulizumab-associated rashes and alopecia are common in patients treated for mycosis fungoides and Sézary syndrome and may be linked with a good treatment response.

This review discusses the clinical features of hypopigmented mycosis fungoides in primary cutaneous T cell lymphoma and reports no new clinical results.

This study reports that despite rescuing neurulation and skin barrier defects, Grhl3 gene overexpression in mice leads to hearing impairment, hair loss, and other developmental abnormalities, highlighting low tolerance for Grhl3 dysregulation.

In this study, two formulations of platelet-rich plasma and two mesotherapy products showed varying degrees of effectiveness in improving hair thickness, density, and count in androgenetic alopecia patients after six months, with MZT1 and PRP2 achieving statistically significant improvements in most measures.

Researchers demonstrated that a new vaccine platform using antigen-loaded hydrogels enhanced humoral immune responses in mice, producing stronger antigen-specific antibody levels compared to the conventional adjuvant Alum, and offering promising protective capabilities against influenza virus.

This study presented a case where a 23-year-old woman with alopecia induced by hyaluronic acid injections experienced full hair regrowth using a combination of Concentrated Growth Factor, microneedling, and minoxidil, and also reviewed literature noting variable success rates with other treatments.

This study found that the MD-3 antibody significantly improved the survival of hair follicle allografts in nonhuman primates by reducing T-cell infiltration.

This study identified a recurrent mutation in the endothelin receptor type A associated with mandibulofacial dysostosis with alopecia, and proposed a mechanism involving increased ligand affinity due to structural changes.

This study found that extracts from the rice variety Bue Bang 3 CMU, particularly the husk and bran, demonstrated antioxidant, anti-inflammatory, and anti-androgenic properties, suggesting potential use in treating androgenetic alopecia.

ACTH promotes hair growth in mink, but α-MSH does not.

This study found significant hair regrowth in male pattern baldness using 2% and 3% topical minoxidil solutions compared to placebo over a 4-month period.

In this study, deleting the gene Mettl3 in mouse epidermal progenitors resulted in impaired epithelial development and self-renewal, highlighting m⁶A's crucial role in regulating chromatin modifiers and maintaining normal epithelial tissue function.

In this randomized controlled trial, combining 4-weekly microneedling with 5% minoxidil significantly increased hair density and diameter in men with androgenetic alopecia compared to minoxidil alone, while side effects were minor and tolerable.

This study reviewed treatments and findings related to male androgenetic alopecia, noting that topical minoxidil and oral finasteride are effective for slowing hair loss, while newer interventions like PRP and microneedling show promise.

This study found that GelMA/HAMA bioink shows promise for 3D printing skin equivalents, as it effectively mimics the native skin's properties and supports hair follicle structure development.

In this randomized controlled study, the researchers found that an herbal extract combination showed similar efficacy to 3% minoxidil solution in treating androgenetic alopecia over 24 weeks, with no significant safety concerns, suggesting it might be a viable alternative treatment.

In this study, researchers developed a biocompatible, ROS-responsive hydrogel to deliver miR-665 locally, effectively reducing inflammatory signaling and promoting hair follicle regeneration in an alopecia areata mouse model, offering a promising approach for targeted treatment.

This study found that combining microneedling with 5% minoxidil significantly improved hair appearance in androgenetic alopecia patients, with high patient satisfaction and no severe adverse events.

This study suggests that activating AMPK to phosphorylate ZDHHC13 may enhance MC1R function and reduce melanoma risk in individuals with red hair.